Literature DB >> 24249680

Cost-utility analysis of a multidisciplinary strategy to manage osteoarthritis of the knee: economic evaluation of a cluster randomized controlled trial study.

Carlo A Marra1, Maja Grubisic, Jolanda Cibere, Kelly A Grindrod, John C Woolcott, Louise Gastonguay, John M Esdaile.   

Abstract

OBJECTIVE: To determine if a pharmacist-initiated multidisciplinary strategy provides value for money compared to usual care in participants with previously undiagnosed knee osteoarthritis.
METHODS: Pharmacies were randomly allocated to provide either 1) usual care and a pamphlet or 2) intervention care, which consisted of education, pain medication management by a pharmacist, physiotherapy-guided exercise, and communication with the primary care physician. Costs and quality-adjusted life-years (QALYs) were determined for patients assigned to each treatment and incremental cost-effectiveness ratios (ICERs) were determined.
RESULTS: From the Ministry of Health perspective, the average patient in the intervention group generated slightly higher costs compared with usual care. Similar findings were obtained when using the societal perspective. The intervention resulted in ICERs of $232 (95% confidence interval [95% CI] -1,530, 2,154) per QALY gained from the Ministry of Health perspective and $14,395 (95% CI 7,826, 23,132) per QALY gained from the societal perspective, compared with usual care.
CONCLUSION: A pharmacist-initiated, multidisciplinary program was good value for money from both the societal and Ministry of Health perspectives.
Copyright © 2014 by the American College of Rheumatology.

Entities:  

Mesh:

Year:  2014        PMID: 24249680     DOI: 10.1002/acr.22232

Source DB:  PubMed          Journal:  Arthritis Care Res (Hoboken)        ISSN: 2151-464X            Impact factor:   4.794


  7 in total

1.  Opinions and preferences of British Columbia pharmacists and physicians on medication management services.

Authors:  Nicole W Tsao; Amir Khakban; Louise Gastonguay; Zafar Zafari; Larry D Lynd; Carlo A Marra
Journal:  Can Pharm J (Ott)       Date:  2016-10-12

Review 2.  Global health policy in the 21st century: Challenges and opportunities to arrest the global disability burden from musculoskeletal health conditions.

Authors:  Andrew M Briggs; Jeremy Shiffman; Yusra Ribhi Shawar; Kristina Åkesson; Nuzhat Ali; Anthony D Woolf
Journal:  Best Pract Res Clin Rheumatol       Date:  2020-07-23       Impact factor: 4.098

3.  A systematic review of economic evaluations of conservative treatments for chronic lower extremity musculoskeletal complaints.

Authors:  Linda Fenocchi; Jody L Riskowski; Helen Mason; Gordon J Hendry
Journal:  Rheumatol Adv Pract       Date:  2018-09-10

4.  The potential role of community pharmacy staff in reducing patient delay in consulting with symptoms of rheumatoid arthritis: a qualitative study.

Authors:  Gwenda Simons; Nour Ismail; Karim Raza; Marie Falahee; Karanbir Sandhu; Christian D Mallen; Rebecca J Stack; Sarah Pontefract
Journal:  BMC Rheumatol       Date:  2022-08-24

5.  Effectiveness and efficiency of an 11-week exercise intervention for patients with hip or knee osteoarthritis: a protocol for a controlled study in the context of health services research.

Authors:  Inga Krauss; Gerhard Mueller; Georg Haupt; Benjamin Steinhilber; Pia Janssen; Nicola Jentner; Peter Martus
Journal:  BMC Public Health       Date:  2016-04-30       Impact factor: 3.295

6.  Costing Methodology and Key Drivers of Health Care Costs Within Economic Analyses in Musculoskeletal Community and Primary Care Services: A Systematic Review of the Literature.

Authors:  Roanna Burgess; James Hall; Annette Bishop; Martyn Lewis; Jonathan Hill
Journal:  J Prim Care Community Health       Date:  2020 Jan-Dec

7.  Cost-Effectiveness Analysis of the Treatment Strategies with or without Opioid Medications in Surgery-Eligible Patients with Osteoarthritis in Japan.

Authors:  Tomoyuki Takura; Akira Yuasa; Naohiro Yonemoto; Sven Demiya; Hiroyuki Matsuda; Nozomi Ebata; Koichi Fujii; Muneaki Ishijima
Journal:  Pharmacoecon Open       Date:  2021-08-10
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.